Table 2 Impact of COVID-19 on the continuation of ongoing clinical trials
Trials continued with modifications | Trials continued without modifications | Trials put on hold | |||
|---|---|---|---|---|---|
N of organisations (%) | Proportion of trials | N of organisations (%) | Proportion of trials | N of organisations (%) | Proportion of trials |
2 (11) | None | 1 (6) | None | 2 (11) | None |
4 (22) | 1–25% | 9 (50) | 1–25% | 7 (39) | 1–25% |
3 (17) | 26–50% | 6 (33) | 26–50% | 5 (28) | 26–50% |
4 (22) | 51–75% | 1 (6) | 51–75% | 2 (11) | 51–75% |
5 (28) | 76–99% | 0 (0) | 76–99% | 2 (11) | 76–99% |
0 (0) | 100% | 1 (6) | 100% | 0 (0) | 100% |